Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

The advent of iPSCs has brought about a significant transformation in stem cell research,
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …

Lung cancer is one of the most common cancers worldwide and the leading cause of death.
Early screening of lung cancer is exceptionally essential for later treatment. Abnormal lung …

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly
enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring …

Abstract Non-Small Cell Lung Cancer (NSCLC) represents∼ 85% of all lung cancers and∼
15–20% of them are characterized by mutations affecting the Epidermal Growth Factor …

Head and neck squamous cell carcinoma is a disease that most commonly produce tumours
from the lining of the epithelial cells of the lips, larynx, nasopharynx, mouth, or oro-pharynx. It …

Simple Summary Non-small-cell lung cancer (NSCLC) patients become resistant to targeted
therapies such as tyrosine kinase inhibitors (TKIs) through mutations in the EGFR gene and …

Dynamic reciprocity between cellular components of the tumor microenvironment and tumor
cells occurs primarily through the interaction of soluble signals, ie, cytokines produced by …

Background Epidermal growth factor receptor (EGFR) is frequently overexpressed in oral
squamous cell carcinoma (OSCC), and EGFR‐targeting therapeutics have been widely …

VEGFR, a receptor tyrosine kinase inhibitor (TKI), is an important regulatory factor that
promotes angiogenesis and vascular permeability. It plays a significant role in processes …